MX2021010989A - Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica. - Google Patents

Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica.

Info

Publication number
MX2021010989A
MX2021010989A MX2021010989A MX2021010989A MX2021010989A MX 2021010989 A MX2021010989 A MX 2021010989A MX 2021010989 A MX2021010989 A MX 2021010989A MX 2021010989 A MX2021010989 A MX 2021010989A MX 2021010989 A MX2021010989 A MX 2021010989A
Authority
MX
Mexico
Prior art keywords
endorphin
combination
adrenocorticotropic hormone
formulation including
compositions
Prior art date
Application number
MX2021010989A
Other languages
English (en)
Inventor
Charles Peter Lollo
Denis J Carlo
Original Assignee
Adamis Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamis Pharmaceuticals Corp filed Critical Adamis Pharmaceuticals Corp
Publication of MX2021010989A publication Critical patent/MX2021010989A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente especificación proporciona composiciones de la hormona ß-endorfina y adrenocorticotrópica (ACTH por sus siglas en inglés). Estas composiciones son útiles en métodos para tratar una enfermedad.
MX2021010989A 2019-03-13 2020-03-12 Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica. MX2021010989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818034P 2019-03-13 2019-03-13
PCT/US2020/022473 WO2020186108A1 (en) 2019-03-13 2020-03-12 FORMULATION INCLUDING A COMBINATION OF β-ENDORPHIN AND ADRENOCORTICOTROPIC HORMONE

Publications (1)

Publication Number Publication Date
MX2021010989A true MX2021010989A (es) 2021-10-01

Family

ID=72427116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010989A MX2021010989A (es) 2019-03-13 2020-03-12 Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica.

Country Status (10)

Country Link
US (1) US20220054595A1 (es)
EP (1) EP3937972A4 (es)
JP (1) JP2022525126A (es)
KR (1) KR20210137535A (es)
AU (1) AU2020237248A1 (es)
CA (1) CA3133084A1 (es)
IL (1) IL286315A (es)
MX (1) MX2021010989A (es)
SG (1) SG11202109652TA (es)
WO (1) WO2020186108A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11285192B2 (en) 2019-03-13 2022-03-29 Adamis Pharmaceuticals Corporation Formulation including a combination of beta-endorphin and adrenocorticotropic hormone
US20240033328A1 (en) * 2020-12-18 2024-02-01 Amzell B.V. Acth in the treatment of an adrenocorticotropic hormone responsive pediatric disorder
WO2022217395A1 (zh) 2021-04-12 2022-10-20 南京汉欣医药科技有限公司 一种高纯的人促肾上腺皮质激素或其类似物及其规模化制备方法
WO2023034819A1 (en) * 2021-08-30 2023-03-09 Mallinckrodt Ard Ip Unlimited Company Pre-filled manual injector apparatus
US11975047B1 (en) 2022-10-28 2024-05-07 Ani Pharmaceuticals, Inc. Methods for storing and warming purified corticotropin compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
GB0600202D0 (en) * 2006-01-06 2006-02-15 Aimsco Ltd Treatment of HIV
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
US11207385B2 (en) * 2015-12-14 2021-12-28 Aequus Biopharma, Inc. Melanocortins and methods of use thereof

Also Published As

Publication number Publication date
AU2020237248A1 (en) 2021-10-28
SG11202109652TA (en) 2021-10-28
KR20210137535A (ko) 2021-11-17
US20220054595A1 (en) 2022-02-24
WO2020186108A1 (en) 2020-09-17
JP2022525126A (ja) 2022-05-11
EP3937972A1 (en) 2022-01-19
EP3937972A4 (en) 2023-01-04
CA3133084A1 (en) 2020-09-17
IL286315A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX2021010989A (es) Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
ZA202007007B (en) Mcl-1 inhibitors
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3826666A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES ASSOCIATED WITH NRP2
MX2019009753A (es) Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
ZA202104166B (en) Sulcardine administration for treatment of acute atrial fibrillation
PH12021550122A1 (en) Solubilized apyrases, methods and use
EP3737355A4 (en) COMPOSITIONS AND METHODS OF TREATING A NERVE INJURY
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
MX2021016050A (es) Formulaciones transdermicas.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2016009600A (es) Agentes para utilizarse en el tratamiento de la inflamacion de retina.
EP3849591A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2020013621A (es) Composiciones y metodos de tratamiento de vih.
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
EP3768095A4 (en) Compositions and methods for treating diarrheal diseases